PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Multimodality imaging features, treatment, and prognosis of post-transplant lymphoproliferative disorder in renal allografts: A case report and literature review.

Abstract Among patients with post-transplant lymphoproliferative disorder (PTLD), there is a high incidence of immunosuppressed transplant recipients. It is necessary to make an early diagnosis to increase the likelihood of a good prognosis.
PMID
Related Publications

Post-transplant lymphoproliferative disorder in adult liver transplant recipients: a South American multicenter experience.

Cessation of immunosuppression during chemotherapy for post-transplant lymphoproliferative disorders in renal transplant patients.

Post-transplant lymphoproliferative disorder: a clinicopathologic study of 15 cases.

Complete response to post-transplant lymphoproliferative disorder by surgical resection and rituximab after living-donor liver re-transplantation for recurrent primary sclerosing cholangitis.

Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience.

Authors

Mayor MeshTerms

Immunocompromised Host

Keywords
Journal Title medicine
Publication Year Start




PMID- 29703027
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 17
DP  - 2018 Apr
TI  - Multimodality imaging features, treatment, and prognosis of post-transplant
      lymphoproliferative disorder in renal allografts: A case report and literature
      review.
PG  - e0531
LID - 10.1097/MD.0000000000010531 [doi]
AB  - RATIONALE: Among patients with post-transplant lymphoproliferative disorder
      (PTLD), there is a high incidence of immunosuppressed transplant recipients. It
      is necessary to make an early diagnosis to increase the likelihood of a good
      prognosis. PATIENT CONCERNS: We report a case of a 54-year-old female patient who
      developed PTLD after liver and kidney transplantation. DIAGNOSES: We aimed to
      analyze the standard diagnosis and follow-up of PTLD with imaging. Radiologists
      need to be familiar with all imaging modalities when dealing with PTLD, including
      ultrasonography, computed tomography, magnetic resonance imaging,
      positron-emission tomography/computed tomography. INTERVENTIONS: The initial
      treatment included both reduction of immunosuppression and rituximab. Then the
      treatment strategy changed to rituximab and chemotherapy. Finally, the treatment 
      strategy combined glucocorticoid therapy. OUTCOMES: The patient was in a stable
      condition at the 3-month follow-up. LESSONS: Systematic evaluation of the various
      imaging modalities, treatment options, and prognoses of PTLD in renal allografts 
      suggested that in cases with a poor prognosis, the proper imaging modalities
      provide essential information with regard to the determination of the appropriate
      treatment.
FAU - Li, Jianming
AU  - Li J
AD  - Department of Ultrasound.
FAU - Liu, Yujiang
AU  - Liu Y
AD  - Department of Ultrasound.
FAU - Wang, Zhenchang
AU  - Wang Z
AD  - Department of Radiology, Capital Medical University, Beijing, China.
FAU - Hu, Xiangdong
AU  - Hu X
AD  - Department of Ultrasound.
FAU - Xu, Ruifang
AU  - Xu R
AD  - Department of Ultrasound.
FAU - Qian, Linxue
AU  - Qian L
AD  - Department of Ultrasound.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Glucocorticoids)
RN  - 4F4X42SYQ6 (Rituximab)
SB  - AIM
SB  - IM
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - *Immunocompromised Host
MH  - Kidney Transplantation/adverse effects
MH  - Liver Transplantation/adverse effects
MH  - Lymphoproliferative Disorders/*diagnostic imaging/drug
      therapy/etiology/immunology
MH  - Middle Aged
MH  - Multimodal Imaging/*instrumentation/*methods
MH  - Rituximab/therapeutic use
PMC - PMC5944490
EDAT- 2018/04/29 06:00
MHDA- 2018/05/15 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
AID - 10.1097/MD.0000000000010531 [doi]
AID - 00005792-201804270-00059 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(17):e0531. doi: 10.1097/MD.0000000000010531.